JP2002508338A5 - - Google Patents

Download PDF

Info

Publication number
JP2002508338A5
JP2002508338A5 JP2000538720A JP2000538720A JP2002508338A5 JP 2002508338 A5 JP2002508338 A5 JP 2002508338A5 JP 2000538720 A JP2000538720 A JP 2000538720A JP 2000538720 A JP2000538720 A JP 2000538720A JP 2002508338 A5 JP2002508338 A5 JP 2002508338A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
hiv
composition according
lentivirus
vector
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2000538720A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002508338A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US1998/025720 external-priority patent/WO1999030742A1/en
Publication of JP2002508338A publication Critical patent/JP2002508338A/ja
Publication of JP2002508338A5 publication Critical patent/JP2002508338A5/ja
Pending legal-status Critical Current

Links

JP2000538720A 1997-12-12 1998-12-11 レンチウィルスベクターの治療使用 Pending JP2002508338A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6957997P 1997-12-12 1997-12-12
US60/069,579 1997-12-12
PCT/US1998/025720 WO1999030742A1 (en) 1997-12-12 1998-12-11 Therapeutic use of lentiviral vectors

Publications (2)

Publication Number Publication Date
JP2002508338A JP2002508338A (ja) 2002-03-19
JP2002508338A5 true JP2002508338A5 (pt) 2006-01-26

Family

ID=22089926

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000538720A Pending JP2002508338A (ja) 1997-12-12 1998-12-11 レンチウィルスベクターの治療使用

Country Status (6)

Country Link
EP (1) EP1037669A4 (pt)
JP (1) JP2002508338A (pt)
KR (1) KR20010033062A (pt)
AU (1) AU749059B2 (pt)
CA (1) CA2314683A1 (pt)
WO (1) WO1999030742A1 (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1964573B1 (en) 1999-10-22 2014-11-26 Aventis Pasteur Limited Method of inducing and/or enhancing an immune response to tumor antigens
US6656706B2 (en) 1999-12-23 2003-12-02 The United States Of America As Represented By The Department Of Health And Human Services Molecular clones with mutated HIV gag/pol, SIV gag and SIV env genes
US7851212B2 (en) 2000-05-10 2010-12-14 Sanofi Pasteur Limited Immunogenic polypeptides encoded by MAGE minigenes and uses thereof
US6712612B1 (en) 2000-12-12 2004-03-30 Genecure Llc Safe and stable retroviral helper cell line and related compositions and methods
JP2006516548A (ja) 2002-12-30 2006-07-06 アンジオテック インターナショナル アクツィエン ゲゼルシャフト 迅速ゲル化ポリマー組成物からの薬物送達法
ES2298745T3 (es) 2003-04-24 2008-05-16 Fondazione Centro San Raffaele Del Monte Tabor Promotores bidireccionales de sintesis y utilizacion de los mismos.
AU2008314485B9 (en) 2007-10-15 2015-02-26 Jingang Medicine (Australia) Pty Ltd Expression system for modulating an immune response
US9795658B2 (en) 2010-04-20 2017-10-24 Admedus Vaccines Pty Ltd Expression system for modulating an immune response
US10596248B2 (en) 2015-12-09 2020-03-24 Jingang Medicine (Australia) Pty Ltd Immunomodulating composition for treatment
WO2018018082A1 (en) 2016-07-26 2018-02-01 The Australian National University Immunostimulatory compositions and uses therefor

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3325579B2 (ja) * 1995-03-16 2002-09-17 久光製薬株式会社 新規遺伝子組換え体
US5650309A (en) * 1995-05-16 1997-07-22 The Regents Of The University Of California Viral vectors
US6013516A (en) * 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
EP0863988A1 (en) * 1995-11-28 1998-09-16 Clinical Technologies, Inc. Recombinant hiv and modified packaging cells and method for treating acquired immune deficiency syndrome
DK0871757T3 (da) * 1995-11-28 2003-07-14 Univ Johns Hopkins Med Konditionelt replikerende virale vektorer og deres anvendelse
DE69739372D1 (de) * 1996-02-21 2009-06-04 Immunity Kft. Genetic Verfahren und zusammensetzungen zur genetisch schützenden und therapeutischen immunisierung
EP0885302A1 (en) * 1996-03-05 1998-12-23 The Regents Of The University Of California Recombinant live feline immunodeficiency virus and proviral dna vaccines
AU734968B2 (en) * 1996-07-22 2001-06-28 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Vectors for inhibiting HIV and tumor growth
JP2001513643A (ja) * 1997-03-06 2001-09-04 ウーベルラ、クラウス レンチウイルスをベースとするベクター及びベクター系
GB9704977D0 (en) * 1997-03-11 1997-04-30 Univ Glasgow FIV vaccine
EP1003894A2 (en) * 1997-07-18 2000-05-31 Chiron Corporation Lentiviral vectors

Similar Documents

Publication Publication Date Title
PL397776A1 (pl) Kompleks rozpuszczalny obejmujący retrowirusową glikoproteinę powierzchniową oraz kompozycja obejmująca ten kompleks
WO1990015066A3 (fr) Sequences nucleotidiques issues du genome des retrovirus du type hiv-1, hiv-2 et siv, et leurs applications notamment pour l'amplification des genomes de ces retrovirus et pour le diagnostic in vitro des infections dues a ces virus
CA2022539A1 (en) Albumin derivatives with therapeutic functions
TR200001553T2 (tr) HIV-1 Tat veya bunun türevleri.
WO2001010456A3 (en) Peptides that block viral infectivity and methods of use thereof
ATE264914T1 (de) Antivirale proteine, dafür kodierende dna, und deren verwendung
EA200200724A1 (ru) Вакцина для профилактической или терапевтической иммунизации против вируса иммунодефицита человека (вич)
JP2002508338A5 (pt)
MXPA02007478A (es) Vacuna contra el virus de inmunodeficiencia humana.
EP1637518A3 (en) Inhibitors of aspartyl protease
WO2000061067A3 (fr) Vaccin anti-vih-1 comprenant tout ou partie de la proteine tat de vih-1
NO940810L (no) Behandling av virusinfeksjoner
CA2195125A1 (en) Difluorostatone antiviral agents
WO1996001110A3 (en) Anti-hiv triple combination
JP2002523426A5 (pt)
EP0323157A3 (en) Antiviral compounds and methods
WO2000018433A3 (en) Use of antigenic complexes of hiv envelope and hla class i antigens as hiv vaccine
RU96116005A (ru) Штамм hominis immunodeficiti virus (hiv-i) вич-i/россия/гм-12-95 (ru1295) субтипа в для диагностических и вакцинных препаратов
FR2647809B1 (fr) Amorces oligonucleotidiques pour l'amplification du genome des retrovirus du type hiv-1, hiv-2 et siv, et leurs applications au diagnostic in vitro des infections dues a ces virus
DK0685235T3 (da) Ekstrakter af Piliostigma thonningii, anvendelse heraf og formuleringer, som indeholder dem
NO963254D0 (no) Makrocykliske difluorstatonderivater som er anvendbare som antivirale midler
RU2003116404A (ru) Штамм вируса западного энцефаломиелита лошадей (western encephalomyelitis virus-wee 163-a) гкв n 964 для приготовления диагностических и профилактических препаратов
AU2470295A (en) High-affinity ligands of insulin receptor antibodies, tachykinin substance p, hiv integrase and hiv-1 reverse transcriptase
RU2002126506A (ru) Субстрат для определения активности интегразы вируса иммунодефицита человека
JPH03173886A (ja) キノリルオキサゾール―２―オン類による糖蛋白エンベロープを着たウィルスの感染力の防止